Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10426958 | 0.81 | TDP1 (0.53) | CYP1A2CYP2C19RAB9ANPC1CYP2D6 | |
| SCHEMBL3135172 | 0.77 | TDP1 (0.53) | CYP1A2CYP2C19RAB9ANPC1CYP2D6 | |
| SCHEMBL24177880 | 0.73 | POLB (0.40) | CYP1A2CYP2C19RAB9ANPC1CYP2D6 | |
| SCHEMBL28725429 | 0.73 | POLB (0.40) | CYP1A2CYP2C19RAB9ANPC1CYP2D6 | |
| SCHEMBL29225055 | 0.73 | POLB (0.43) | CYP1A2CYP2C19RAB9ANPC1CYP2D6 | |
| SCHEMBL9802746 | 0.73 | KDM4E (0.50) | CYP1A2CYP2C19RAB9ANPC1CYP2D6 | |
| SCHEMBL18073236 | 0.73 | ALDH1A1 (0.53) | CYP1A2CYP2C19RAB9ANPC1CYP2D6 | |
| SCHEMBL10513605 | 0.71 | CYP1A2 (0.46) | CYP1A2CYP2C19RAB9ANPC1CYP2D6 | |
| SCHEMBL5456883 | 0.70 | KMT2A (0.39) | CYP1A2CYP2C19RAB9ANPC1CYP2D6 | |
| SCHEMBL23121598 | 0.70 | KMT2A (0.39) | CYP1A2CYP2C19RAB9ANPC1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024140968-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD AND USE THEREFOR | 广州市联瑞制药有限公司 | 2024-07-04 | — | — | WO | disclosed |
| US-20240059671-A1 | TYROSINE KINASE 2 (TYK2) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2024-02-22 | — | — | US | disclosed |
| CN-116490501-A | Tyrosine kinase 2 (TYK 2) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2023-07-25 | — | — | CN | disclosed |
| WO-2022100710-A1 | TYROSINE KINASE 2 (TYK2) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2022-05-19 | — | — | WO | disclosed |
| WO-2017172596-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION (US) | 2017-10-05 | — | — | WO | disclosed |
| US-5068334-A | Analgesics and antipyretics | KARL THOMAE GMBH (DE) | 1991-11-26 | — | — | US | disclosed |
| EP-0338228-A2 | Use of quinoline-2,5-diones in a medicament having an analgesic, antipyretic and/or antiphlogistic activity | Dr. Karl Thomae GmbH (DE) | 1989-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059671-A1 | TYROSINE KINASE 2 (TYK2) DEGRADATION COMPOUNDS AND METHODS OF USE | TYK2, ERBB2, PTK2B | CYP1A2 2254/4885CYP2C19 2667/4885RAB9A 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.